AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 291 min read$MNKD

Binder Steven B. sold $128K of MNKD

Binder Steven B. sold 39,051 shares of MANNKIND CORP (MNKD) at $3.29 ($0.13M total) on 2026-09-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Binder Steven B.
Published Sep 29, 2026, 12:26 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 2:52 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MNKD
Neutral
high confidence
Mentioned
$MNKD
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MNKDNeutralLow
01

Why it matters

A modest insider sell may cause short‑term price softness, but the overall impact is limited given the small dollar amount.

02

Market read

Primary disclosure of a small insider sale; low trading relevance.

03

What to watch

The director remains a large holder (over 700k shares), suggesting continued confidence.

Relevance 3/10Novelty 3/10Timing: after‑hours filing

Background

SEC Form 4 filing discloses insider transactions; such filings are required to be reported promptly.

Company-level read

Ticker impact

$MNKDNeutralHigh confidence
Context

Director Binder Steven B. sold 39,051 shares for $128,477 via a 10b5‑1 plan, reducing his stake to 713,258 shares.

Expected impact

likely slight downward pressure as the market prices in the insider sell

Evidence & confidence

Form 4 is a primary source; the transaction size is modest, so impact is limited.

Market effects

Sector

Minimal; ManKind operates in the cannabis sector, but a small insider sale does not affect sector outlook.

Regional

None; the filing is company‑specific.

Global

None

Counterpoint

What could challenge this read

The sale could be routine under a pre‑arranged plan and not indicative of future weakness.

Key entities

  • company
    ManKind Corp.

    US‑listed cannabis company (ticker MNKD).

  • person
    Binder Steven B.

    Director of ManKind Corp.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MNKD insider trading history →

Related articles

AUG 24
$UTHRMedAI 9/10

FDA accepts United Therapeutics' ralinepag NDA for PAH

The FDA accepted United Therapeutics' NDA for ralinepag, a PAH treatment, with a PDUFA target date of June 24, 2027. The application is based on Phase III trial results showing a 55% reduction in clinical worsening events. If approved, ralinepag would be the first once-daily oral prostacyclin IP receptor agonist for PAH. The company also plans to develop a dry powder inhalation formulation with MannKind.

allsci.com2 min
AUG 10
$MNKDMed

CT companies take different paths to finance growth

Three Connecticut firms outlined different financing paths. New Silver said it acquired Mayflower Venture Partners to expand lending in New England, with deal terms undisclosed. American Battery Materials filed to raise about $16.3M for Utah lithium and magnesium exploration, targeting production in 2029. MannKind raised $50M after FDA approval of Furoscix ReadyFlow, funding a $45M milestone payment and aiming for U.S. sales by end-August.

hartfordbusiness.com6 min
AUG 5
$MNKDMedAI 8/10

MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update

MANNKIND CORP (MNKD) filed an SEC Form 8-K — Results of Operations and Financial Condition. MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update • Achieved three major catalysts to drive future growth: o Launched the pediatric indication of Afrezza ® following FDA approval o FUROSCIX ReadyFlow™ autoinjector approved for treatment of edema

SEC EDGAR 8-K4 min